Overview Of The Top 5 Vaccine Companies In China

Due to the prevalence of variousdiseases, people are also aware of the need for vaccination. Vaccinations aregiven to increase specific immunity in the body and reduce the risk ofspreading the disease and the severity of the disease. Let's briefly introducethe top 5 vaccine companies in China.

Founded in 1989, China National Biotechnology Corporation is the firstamong the top 5 vaccine companies. It was originally an important state-ownedbackbone enterprise managed by the State-owned Assets Supervision andAdministration Commission of the State Council. In September 2009, with theapproval of the State Council, China National Pharmaceutical Group Corporationand China National Biotechnology Corporation carried out joint reorganization.So far, SASAC has adjusted from 136 enterprises to 135 enterprises to performthe duties of investors. The China National Scientific Equipment Import andExport Corporation and China Medical and Health Equipment Import and ExportCorporation, both affiliated to Zhongsheng Group, have extensive customergroups and mature sales networks at home and abroad, and have a long historyand high reputation in China's science and technology and medical and healthfields.

Hualan Bioengineering Co., Ltd. isthe second among the top 5 vaccine companies. Founded in 1992, it is a nationalkey high-tech enterprise engaged in the research and development and productionof blood products. In 1998, it was the first to pass the blood products industryGMP certification. As a large-scale biological product manufacturer designatedby the state, the company has strong technical development strength, leadingtechnical level, first-class production and testing equipment, scientific andstandardized management and perfect quality assurance system. At present, thecompany is a blood product manufacturer with the largest variety of productsand the most complete specifications in China, and its plasma processingcapacity ranks among the top in China and even in Asia, which indicates thatthe company has become a large blood product manufacturer in Asia. Among them,the domestic market share of the leading products ranks in the forefront of thesame industry, and the main financial indicators have grown rapidly for manyyears, creating a miracle of rapid development of biopharmaceuticalenterprises. The comprehensive strength company has entered the top 30 ofChina's national pharmaceutical industry.

Beijing Tiantan Biological ProductsCo., Ltd. is an enterprise engaged in the research, production and managementof vaccines, blood preparations, diagnostic products and other biologicalproducts. It was launched and listed on the Shanghai Stock Exchange by BeijingInstitute of Biological Products in 1998, and the controlling shareholder isChina Biotechnology Group Corporation. With the development of the company nowhas changchun Qi Jian Biological products Co., LTD., several single collectionof plasma companies and other holding subsidiaries. Tiantan biological has morethan 110 kinds of products, including hepatitis B vaccine, poliomyelitisvaccine, MMR vaccine, Japanese encephalitis vaccine, influenza vaccine,varicella vaccine, human serum albumin, iv human immunoglobulin and so on. Itis an important production base of national immunization program vaccine.

Liaoning Chengda Biological Co.,LTD., the fourth of the top 5 vaccine companies, was established in June 2002.The company takes "providing high-quality biological products, protectinghuman life and health" as its corporate mission, always adhering to thecore values of "integrity, love, harmony, responsibility andcooperation", adhering to the corporate philosophy of "Onlyresponsibility in the face of life", and is committed to becoming aninternational excellent biopharmaceutical enterprise. Main products for humanrabies vaccine and human je inactivated vaccine. Chengda Biological productionof human rabies vaccine in the domestic market share has always maintained aleading, domestic marketing network covers nearly 2000 district and county CDC,and occupies a dominant position in the international market, product sales tomore than 30 countries and regions.

Yunnan Watson Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research,development, production and sales of human vaccine products. It is committed toproviding safe, effective, high-quality and technologically advanced humanvaccine products to domestic and foreign markets. On March 18, 2020, Watson Bioranked 26th in the "2020 Hurun China Top 100 Healthy PrivateEnterprises" with a market value of 44 billion yuan. On May 11, 2020,Watson Bio announced that it signed a "Technology Development CooperationAgreement" with Aibo Bio. Work together to carry out preclinical research,clinical trials of mRNA new crown vaccine, and implement commercial production.On July 21, 2021, the domestically produced mRNA new crown vaccine cooperatingwith Watson Bio and Aibo Bio will conduct Phase III clinical trials in China. InJanuary 2022, Watson Bio announced that Yuxi Watson, a holding subsidiary ofthe company, received the "Marketing License" for the 13-valentpneumococcal polysaccharide conjugate vaccine issued by the Moroccan Ministryof Health and Social Security. This is also the first time that Watson Bio's13-valent pneumonia vaccine has been approved overseas.

The vaccines produced by the top 5vaccine companies in China are all safe and effective, with minimal sideeffects. Therefore, there is no need to worry too much about the adversereactions of the vaccine when vaccinating.